Medication non-adherence poses considerable challenges in managing chronic diseases and is associated with almost 200,000 deaths and €80-125 billion of potentially preventable direct (e.g. hospitalizations, waste of medication) and indirect (e.g. work productivity losses) costs in the European Union alone. The increasing awareness of the contribution of the acceptability of drug products by the patient to medication adherence and clinical outcomes is driving the integration of Patient Centric drug Product Design (PCDPD) into the pharmaceutical development process.
Regulatory agencies have addressed the relevancy of placing the patient in the center of pharmaceutical development. EMA has issued guideline/reflection papers for pediatric and older populations while FDA has developed a series of guidance documents on patient focused drug development with the primary goal to better incorporate the patient’s voice in drug development and evaluation.
PCDPD can be defined as the process of identifying the comprehensive needs of the target patient population to support the design of drug products. Three major factors are analyzed in PCDPD, namely patient, drug and drug product characteristics. This systematic approach integrates this insight which is translated to a Target Product Profile (TPP) to drive the pharmaceutical product design process.
Two case studies will be presented focused on the pediatric population and on patients with a chronic skin disorder (psoriasis) which will highlight the roadmap for a successful PCDPD.
- 30 Reads